Table 1.
Patient Characteristics (n = 41)
| Characteristic | n. (%) or median [range] |
|---|---|
| Gender | |
| Female | 19 (46) |
| Male | 22 (54) |
| Median age, years | 36 [16–74] |
| Histological subtype | |
| Nodular sclerosis | 28 (68) |
| Mixed cellularity | 6 (15) |
| Lymphocyte-rich | 2 (5) |
| Not classified | 5 (12) |
| ECOG PS | |
| 0–1 | 37 (90) |
| ≥2 | 4 (10) |
| Stage at the time of BVB initiation | |
| II | 13 (32) |
| III | 14 (34) |
| IV | 14 (34) |
| Systemic symptomsa | 15 (37) |
| Previous radiation therapy | 14 (34) |
| Previous HDT-ASCT | 8 (20) |
| Previous AlSCT | 2 (5) |
| N. previous lines of therapy | |
| ≤2 | 28 (68) |
| ≥3 | 13 (32) |
| Median N. previous therapies | 2 [1–5] |
| Primary refractory | 28 (68) |
| Relapsed | 13 (32) |
| Previous BV | 26 (63) |
| BV-refractory | 16 (39) |
Abbreviations: AlSCT: allogenic stem cell transplantation; BV: brentuximab vedotin; BVB: brentuximab vedotin and bendamustine; ECOG PS: Eastern Cooperative Oncology Group Performance Status; HDT-ASCT: high-dose therapy-autologous stem cell transplantation.
a
Includes: Night sweats, recurrent fevers, and unexplained ≥ 10% weight loss.